Stifel Nicolaus Raises NewLink Genetics Corporation (NASDAQ:NLNK) Price Target to $29.00

NewLink Genetics Corporation (NASDAQ:NLNK) had its target price lifted by Stifel Nicolaus from $25.00 to $29.00 in a research note released on Friday, November 3rd, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

Several other research firms also recently commented on NLNK. ValuEngine downgraded shares of NewLink Genetics Corporation from a sell rating to a strong sell rating in a report on Tuesday, September 26th. Cantor Fitzgerald reaffirmed a buy rating and issued a $26.00 target price on shares of NewLink Genetics Corporation in a research note on Monday, September 25th. Zacks Investment Research cut shares of NewLink Genetics Corporation from a hold rating to a sell rating in a research report on Wednesday, July 12th. Robert W. Baird upgraded shares of NewLink Genetics Corporation from a neutral rating to an outperform rating and increased their price target for the company from $8.00 to $22.00 in a research report on Friday, September 8th. Finally, Jefferies Group LLC restated a hold rating and issued a $7.00 target price on shares of NewLink Genetics Corporation in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. NewLink Genetics Corporation has a consensus rating of Buy and an average target price of $23.43.

NewLink Genetics Corporation (NASDAQ NLNK) opened at $9.02 on Friday. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17.

TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2017/11/12/newlink-genetics-corporation-nlnk-given-new-29-00-price-target-at-stifel-nicolaus.html.

In related news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the business’s stock in a transaction that occurred on Friday, October 6th. The stock was bought at an average cost of $10.25 per share, for a total transaction of $7,999,991.75. Following the purchase, the insider now owns 7,857,732 shares in the company, valued at approximately $80,541,753. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 13.70% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of NLNK. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of NewLink Genetics Corporation by 1,823.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 9,735 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in NewLink Genetics Corporation during the 3rd quarter valued at $114,000. State of Wisconsin Investment Board purchased a new stake in NewLink Genetics Corporation during the 2nd quarter valued at $125,000. Trexquant Investment LP raised its holdings in NewLink Genetics Corporation by 39.1% during the 2nd quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 5,097 shares during the period. Finally, Advisor Group Inc. raised its holdings in NewLink Genetics Corporation by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 600 shares during the period. 55.30% of the stock is currently owned by institutional investors and hedge funds.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

The Fly

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply